Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment.
Hsu SK, Li CY, Lin IL, Syue WJ, Chen YF, Cheng KC, Teng YN, Lin YH, Yen CH, Chiu CC. · 2021
Read Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment. by Hsu SK, Li CY, Lin IL, Syue WJ, Chen YF, Cheng KC, Teng YN, Lin YH, Yen CH, Chiu CC. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8419056.txt.
Introduction
Hsu and co-authors review pyroptosis, an inflammation-linked form of programmed cell death, and its place in cancer care. Many past chemotherapies aimed at apoptosis, but tumors often evade that path. Newer death forms such as pyroptosis may open fresh attack routes.
The review explains how pyroptosis drives cancer growth or slows it. It also links this death form to immunity inside tumors. Pyroptosis bridges innate and adaptive immune defense. The authors report that it can boost checkpoint inhibitor drugs and CAR T-cell therapy. They discuss the switch between apoptosis and pyroptosis as well. The piece frames pyroptosis as a partner for immune therapy.
Catalog record
| CREATOR | Hsu SK, Li CY, Lin IL, Syue WJ, Chen YF, Cheng KC, Teng YN, Lin YH, Yen CH, Chiu CC. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 108 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment By Sheng-Kai Hsu, Chia-Yang Li, I-Ling Lin, Wun-Jyun Syue, Yih-Fung Chen, Kai-Chun Cheng, Yen-Ni Teng, Yi-Hsiung Lin, Chia-Hung Yen, Chien-Chih Chiu Published in: Theranostics DOI: 10.7150/thno.62521 ABSTRACT In recent decades, chemotherapies targeting apoptosis have emerged and demonstrated remarkable achievements. However, emerging evidence has shown that chemoresistance is mediated by impairing or bypassing apoptotic cell death. Several novel types of programmed cell death, such as ferroptosis, necroptosis, and pyroptosis, have recently been reported to play significant roles in the modulation of cancer progression and are considered a promising strategy for cancer treatment. Thus, the switch between apoptosis and pyroptosis is also discussed. Cancer immunotherapy has gained increasing attention due to breakthroughs in immune checkpoint inhibitors; moreover, ferroptosis, necroptosis, and pyroptosis are highly correlated with the modulation of immunity in the tumor microenvironment. Compared with necroptosis and ferroptosis, pyroptosis is the primary mechanism for host defense and is crucial for bridging innate and adaptive immunity. Furthermore, recent evidence has demonstrated that pyroptosis exerts benefits on cancer immunotherapies, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell therapy (CAR-T). Hence, in this review, we elucidate the role of pyroptosis in cancer progression and the modulation of immunity. We also summarize the potential small molecules and nanomaterials that target pyroptotic cell death mechanisms and their therapeutic effects on cancer. INTRODUCTION Programmed cell death (PCD) plays a significant role in homeostasis. One salient example is apoptosis, which has been well established for several decades. This process participates in, for instance, embryo development, the removal of infected cells, and the clearance of aberrant cells 1, 2. Conversely, the loss of apoptosis might lead to uncontrolled cell proliferation due to a failure to abide by cell cycle checkpoints 3. Hence, in recent decades, apoptosis has been considered an important target in drug development for cancer. For example, curcumin - an antioxidant derived from turmeric - modulates reactive oxygen species (ROS) levels and induces apoptosis by upregulating p53 4. However, increasing evidence has indicated that several types of cancer exhibit chemoresistance due to aberrant apoptosis 5. For instance, evidence from published studies indicates that breast cancer cell lines, such as MCF-7 and MDA-MB-231 cells, are resistant to docetaxel due to elevated expression of miRNA-34a and miR-141 and the suppression of apoptosis 6. Furthermore, Zeinab suggested that ovarian cancer cells exhibit chemoresistance to cisplatin by upregulating miR-221/222 to directly inhibit PTEN (a tumor suppressor) 7. Thus, a strategy that involves bypassing apoptosis and activating nonapoptotic programmed cell death (e.g., pyroptosis) appears promising for cancer treatment. Pyroptosis is a novel nonapoptotic form of programmed cell death that is strongly associated with the inflammatory response and is also called secondary necrosis 8. It is primarily triggered by inflammasomes and executed by caspases (e.g., caspase-1/-3/-4/-5/-8/-11) and the gasdermin protein family 9-11. Physiologically, pyroptosis serves as an initiator in innate immunity by inducing the release of cytokines, including IL-1β and IL-18, and other molecules, such as high-mobility group protein 1 (HMGB1) and ATP, after cell membrane rupture 12, 13. Intriguingly, accumulating evidence has indicated that pyroptosis plays an important role in the modulation of cancer progression. For example, an experiment conducted by Qiao and colleagues suggested that 2‐(α-naphthoyl)ethyl‐trimethylammonium iodide (α-NETA), a reversible choline acetyltransferase inhibitor, can suppress the proliferation of multiple epithelial ovarian cancer cell lines by inducing caspase-4-triggered pyroptosis 14. In contrast, Hou et al. indicated that programmed death-ligand 1 (PD-L1) translocates to the nucleus of hypoxic cells and upregulates the expression of gasdermin C (GSDMC). This effect eventually contributes to noncanonical caspase-8-mediated pyroptosis in breast cancer but a poor probability of overall survival 11. Additionally, apoptosis shares a similar upstream molecular mechanism with caspase-3-dependent pyroptosis; therefore, the correlation and switch between pyroptosis and apoptosis is worth discussing 15. In addition to bypassing defective apoptosis, several nonapoptotic cell deaths (e.g., necroptosis and pyroptosis) are highly associated with the immune response; nevertheless, their association with tumorigenesis remains to be elucidated 16. Furthermore, recent studies have mainly focused on the adaptive immune response and modulation of cancer due to evolutionary discoveries on immune checkpoints, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), and their application in the clinic; however, the relationship between the innate immune response and cancer treatment has been less investigated 17. Therefore, in this review, we shed light on the correlation between pyroptosis and its role in antitumor immunity and the modulation of cancer progression. CELLULAR PHYSIOLOGY OF PYROPTOSIS IN HOST DEFENSE Apoptosis is a form of noninflammatory programmed cell death. In contrast, primary necrosis (accidental cell death) is mainly caused by cellular responses to stresses, such as ischemia, infection, and trauma, and ultimately leads to the release of immunostimulatory components and unmodified damage-associated molecular patterns (DAMPs). In addition, cell swelling and loss of plasma membrane integrity are observed in necrosis 18, 19. Pyroptosis, a programmed cell death associated with the inflammatory response, is also called secondary necrosis, and secondary necrosis is considered the outcome of complete apoptosis. After apoptosis is initiated, apoptotic cells disintegrate into bodies or vesicles comprising intracellular components and are then phagocytized by scavengers (e.g., macrophages). If apoptotic cells are not removed by phagocytosis, secondary necrosis occurs, despite eat-me signals (engulfment signals expressed on apoptotic cells). Subsequently, this process contributes to a series of events (e.g., cell swelling and a loss of cell membrane integrity) that culminate in plasma membrane rupture and the release of inflammatory stimuli 8, 20, 21. Therefore, Wyllie named this cell autolysis secondary necrosis to distinguish it from primary necrosis 22. Pyroptotic cell death is primarily observed in professional immune cells (i.e., macrophages and dendritic cells). This process was first described in 1992 when macrophages were observed to execute host cell death after infection with Shigella flexneri, a gram-negative bacterium 23. The characteristics of pyroptosis are described below. (1) Executor proteins (gasdermin family members, N-termini) translocate to the cell membrane and oligomerize to form pores, which is similar to observations of mixed-lineage kinase domain-like pseudokinase (MLKL) in necroptosis. Most gasdermin pores (e.g., gasdermin D) have inner diameters of approximately 10-14 nm 6, 24, and the size of these pores facilitates the secretion of IL-1β and IL-18 (diameters of approximately 4.5 nm), which are involved in several cellular events, such as inflammation, proliferation, and differentiation 13, 24-26. (2) Gasdermin-forming pores are nonselective channels for different ions and promote water influx and cell swelling, in contrast to the formation of selective ion channels and the marked changes in intracellular osmolality observed in necroptosis 27, 28. (3) Continuous water influx is driven by osmotic pressure, further resulting in membrane blebbing with bubble-like protrusions (known as pyroptotic bodies) and the ultimate rupture of the plasma membrane 28. This rupture contributes to the release of DAMPs, such as HMGB1 and ATP, and intracellular contents (e.g., lactate dehydrogenase (LDH)) 6, 12, 29 (Figure 1). Intriguingly, most cell lines with activated inflammasomes exhibit resistance to pyroptotic cell death primarily through the recruitment of endosomal sorting complexes required for transport (ESCRT) on the plasma membrane for repair. The mechanism is initiated by the gasdermin D (GSDMD) pore-mediated influx of calcium Ca2+. Hence, the combination of inactive ESCRT-III